• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
【24h】

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials

机译：用Glecaprevir和Pibrentasvir进行的全基因型丙型肝炎治疗8周可改善心血管和代谢结果，并使肾功能稳定：3期临床试验的事后分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionChronic hepatitis C (CHC) infection is associated with extrahepatic manifestations (EHMs) which can affect renal, cardiovascular and other comorbidities. The effect of CHC treatment with short-duration regimens on these EHMs is not well defined. Hence, we examined longitudinal estimated glomerular filtration rate (eGFR), triglycerides and glucose values to assess the impact of short-duration CHC therapy on renal, cardiovascular and metabolic diseases, respectively. MethodsWe conducted analyses of all patients without cirrhosis treated with glecaprevir and pibrentasvir (G/P) for 8?weeks in two phase 3 clinical trials. In addition, one phase 3 trial was carried out to explore the effects of treatment on renal EHMs in patients with advanced renal impairment at baseline. As a sensitivity analysis, we included all CHC patients treated with G/P for 8 or 12?weeks enrolled across five phase 3 trials. Adjusting for baseline demographics and clinical properties via mixed regression models enabled evaluation of changes in EHMs through end of treatment. ResultsG/P treatment for 8?weeks resulted in statistically significant declines in triglycerides (? 28.6?mg/dl) and glucose (? 11.2?mg/dl), while there was no statistically significant decline in eGFR. Biomarker improvements were greatest among patients with elevated triglycerides and elevated glucose at baseline. Similar effects were observed across all patients treated with G/P for 8 or 12?weeks. ConclusionShort-duration treatment with G/P resulted in stable renal function and improvements in cardiovascular and metabolic EHM markers, especially in patients with severe EHMs at baseline. FundingAbbVie Inc.
机译：简介慢性丙型肝炎（CHC）感染与肝外表现（EHM）相关，可影响肾脏，心血管和其他合并症。短期方案进行CHC治疗对这些EHM的影响尚不清楚。因此，我们检查了纵向估计的肾小球滤过率（eGFR），甘油三酸酯和葡萄糖值，以评估短期CHC治疗分别对肾脏，心血管和代谢性疾病的影响。方法我们在两项3期临床试验中，对使用glecaprevir和pibrentasvir（G / P）治疗8周的所有无肝硬化患者进行了分析。此外，进行了一项3期试验，以探讨治疗对基线晚期肾功能不全患者的肾脏EHM的影响。作为敏感性分析，我们纳入了5项3期试验中所有接受G / P治疗8或12周的CHC患者。通过混合回归模型调整基线人口统计学和临床​​特征，可以评估到治疗结束时EHM的变化。结果G / P治疗8周后，甘油三酸酯（？28.6？mg / dl）和葡萄糖（？11.2？mg / dl）下降至统计上显着，而eGFR则无统计学意义。在基线时甘油三酯升高和葡萄糖升高的患者中，生物标志物的改善最大。在接受G / P治疗8或12周的所有患者中均观察到类似的效果。结论G / P短期治疗可稳定肾脏功能，改善心血管和代谢EHM指标，尤其是基线时有严重EHM的患者。资金艾伯维公司

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号